0.787
price up icon21.26%   0.146
after-market 시간 외 거래: .77 -0.017 -2.16%
loading

Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스

pulisher
02:49 AM

Plus Therapeutics (NASDAQ:PSTV) Price Target Raised to $20.00 at Ascendiant Capital Markets - Defense World

02:49 AM
pulisher
Apr 21, 2025

Short Interest in Plus Therapeutics, Inc. (NASDAQ:PSTV) Rises By 34.5% - Defense World

Apr 21, 2025
pulisher
Apr 19, 2025

Plus Therapeutics Appoints Kyle Guse to Board - MSN

Apr 19, 2025
pulisher
Apr 15, 2025

Plus Therapeutics reports progress in CNS cancer treatment By Investing.com - Investing.com Canada

Apr 15, 2025
pulisher
Apr 15, 2025

Plus Therapeutics Inc (NASDAQ: PSTV) Analysts Expect It Could Climb 89.63% From Current Levels. - stocksregister.com

Apr 15, 2025
pulisher
Apr 15, 2025

Plus Therapeutics Presents New Data Highlighting Clinical Benefi - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Plus Therapeutics (PSTV) Unveils Promising Data on REYOBIQ at Upcoming Conference | PSTV Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Plus Therapeutics reports progress in CNS cancer treatment - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Plus Therapeutics Presents New Data Highlighting Clinical - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

New Cancer Drug REYOBIQ Achieves Breakthrough 86% Clinical Benefit in Brain Metastases Study - Stock Titan

Apr 15, 2025
pulisher
Apr 04, 2025

Plus Therapeutics (PSTV) Plans Massive Stock Sale - GuruFocus

Apr 04, 2025
pulisher
Apr 04, 2025

Plus Therapeutics Inc (PSTV) Volatility Hits 17.12% – Here Is What You Should Do - Stocksregister

Apr 04, 2025
pulisher
Apr 01, 2025

Promising Outlook for Plus Therapeutics: Buy Rating Affirmed Amid Clinical and Financial Advancements - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Plus Therapeutics: What’s Fueling the Surge? - timothysykes.com

Apr 01, 2025
pulisher
Mar 31, 2025

PLUS THERAPEUTICS Inc. (PSTV) reports earnings - Quartz

Mar 31, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Estimate for PSTV FY2029 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

HC Wainwright Has Lowered Expectations for Plus Therapeutics (NASDAQ:PSTV) Stock Price - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Plus Therapeutics (NASDAQ:PSTV) Earns “Buy” Rating from D. Boral Capital - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - AOL

Mar 29, 2025
pulisher
Mar 28, 2025

Earnings call transcript: Plus Therapeutics’ Q4 2024 results highlight innovation - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright cuts Plus Therapeutics price target to $5.50 - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright cuts Plus Therapeutics price target to $5.50 By Investing.com - Investing.com Canada

Mar 28, 2025
pulisher
Mar 28, 2025

Promising Outlook for Plus Therapeutics: Strategic Financial Moves and Innovative Assay Launch Justify Buy Rating - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: S - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada

Mar 28, 2025
pulisher
Mar 28, 2025

Plus Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 28, 2025
pulisher
Mar 27, 2025

Plus Therapeutics (PSTV) Reports Mixed FY Results, Revenue Surges - GuruFocus

Mar 27, 2025
pulisher
Mar 27, 2025

Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Plus Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

PLUS THERAPEUTICS Earnings Results: $PSTV Reports Quarterly Earnings - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times

Mar 27, 2025
pulisher
Mar 27, 2025

Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews

Mar 27, 2025
pulisher
Mar 26, 2025

A Peek at Plus Therapeutics's Future Earnings - Benzinga

Mar 26, 2025
pulisher
Mar 25, 2025

PLUS THERAPEUTICS Earnings Preview: Recent $PSTV Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Plus Therapeutics Introduces REYOBIQ - citybiz

Mar 25, 2025
pulisher
Mar 24, 2025

Top Small Cap Stocks To Watch TodayMarch 20th - MarketBeat

Mar 24, 2025
pulisher
Mar 21, 2025

PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Thursday's Trending Pharma Stock Plus Therapeutics, Inc. (Nasdaq: PSTV) Gains 170% - Investorideas.com

Mar 21, 2025
pulisher
Mar 21, 2025

Why Plus Therapeutics Inc. (PSTV) Surged On Thursday? - Insider Monkey

Mar 21, 2025
pulisher
Mar 20, 2025

10 Micro-, Small-Cap Firms Dominate Thursday’s Gains - Insider Monkey

Mar 20, 2025
pulisher
Mar 20, 2025

Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

FDA conditionally accepts new name for Plus Therapeutics drug By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Plus Therapeutics announces FDA conditionally accepted name REYOBIQ - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

FDA conditionally accepts new name for Plus Therapeutics drug - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Why Plus Therapeutics Is Rising In Pre-market? - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - StockTitan

Mar 20, 2025
$20.27
price up icon 0.92%
$71.24
price up icon 2.53%
$32.19
price up icon 0.11%
$27.35
price up icon 8.52%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.52%
자본화:     |  볼륨(24시간):